Laudable steps by FDA leadership in recent weeks to engage diverse stakeholders on advancing innovation for unmet needs. We’re at a pivotal moment in biomedicine—underscored by this week’s ASCO news—a unique chance to change the course of patient care.

https://news.bloomberglaw.com/health-law-and-business/fdas-acting-head-to-meet-closed-door-with-rare-disease-groups